The man with the golden touch appointed CEO of UK biotech C4XD

4 May 2016
dr-clive-dix-big

Clive Dix, a serially successful figure in UK biotech, has been appointed chief executive of UK biotech company C4X Discovery Holdings (AIM:C4XD).

Dr Dix joined the ambitious company, which has the aim of becoming the world’s most productive drug discovery and development company, as non-executive chairman in November 2014. A year later he became executive chairman, with previous chief executive Piers Morgan standing down.

With Dr Dix taking on the chief executive role immediately, non-executive director Sam Williams will become interim chairman while the search for a new chairman takes place.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology